 "Covid-19 sample")
Jubilant Life Sciences on Tuesday said it entered into a non-exclusive licensing agreement with US-based Gilead Sciences to make and sell the latter’s anti-viral drug Remdesivir in 127 countries, including India. The re-purposed Ebola drug is being considered as a potential therapy for coronavirus (Covid-19).
Most of these 127 countries are low-income and lower-middle income nations along with some upper-middle and high-income countries that face significant obstacles to healthcare access.
Under terms of the licensing agreement, Jubilant will have the right to receive a technology transfer of the Gilead manufacturing process and can scale up production. This would, however, be
